HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Healthcare Providers & Services
NAICS:
Administration of Public Health Programs (923120)
SIC:
Computers And Computer Peripheral Equipment And Software (5045)
Contact Information
Investor Relations
MZ North America
Chris Tyson
Executive Vice President
T: 949-491-8235
BEAT@mzgroup.us
Transfer Agent
VStock Transfer
18 Lafayette Place
Woodmere, NY 11598
Company Contact
HeartBeam, Inc.
2118 Walsh Avenue
Suite 210
Santa Clara, CA 95050
T: 408-899-4443